Resalis Therapeutics’ RES-010 Shows Promise in Combating Obesity with Unique Fat-Selective Approach
Table of Contents
A novel RNA-based therapy, RES-010, developed by Resalis Therapeutics, is demonstrating meaningful potential in preclinical trials as a durable adn effective treatment for obesity, offering a distinct approach from existing weight loss medications. The findings, presented at leading scientific conferences including the European Association for the Study of Diabetes (EASD) in Vienna, Austria, highlight RES-010’s ability to reprogram metabolic pathways and achieve substantial fat loss with a favorable safety profile.
RES-010 is an in-class antisense oligonucleotide designed to target microRNA-22 (miR-22), a key regulator of lipid metabolism. unlike many current obesity treatments that primarily focus on appetite suppression,RES-010 aims to reprogram metabolic pathways,offering a potential disease-modifying impact.This targeted approach could lead to sustained weight loss and improved metabolic health by addressing the complex biological factors underlying obesity.
Robust Weight Reduction in Non-Human Primate Study
A recent study evaluated RES-010 in a well-defined non-human primate (NHP) model of obesity. The results, considered highly encouraging due to the close biological similarities between primates and humans, showed robust and durable weight reduction effects in obese NHPs fed a high-fat diet.
After 10 weeks of treatment, RES-010 monotherapy achieved a 15% reduction in fat mass, comparable to the 16% reduction observed with the widely used GLP-1 receptor agonist (GLP-1 RA) semaglutide. Importantly, RES-010 demonstrated a superior safety profile in terms of lean mass preservation, with a -1% change compared to the -8% loss seen with semaglutide.
Additive Benefits and Sustained Results
The combination of RES-010 and semaglutide yielded even more impressive results, resulting in a 33% reduction in fat mass. Perhaps most notably, animals treated with the combination and then maintained on RES-010 alone after semaglutide discontinuation did not experience rebound weight gain, even with increased food intake. Furthermore, four weeks after stopping semaglutide, those continuing RES-010 experienced further fat mass reduction and a substantial recovery of lean mass. The stabilization of body weight observed with RES-010 treatment remained consistent for at least four weeks after treatment ended.
“RES-010 delivers fat-selective weight loss, prevents rebound after GLP-1 RA discontinuation and shows durability beyond treatment, a truly unique feature in treating obesity,” stated a senior official from Resalis Therapeutics. “Because primates closely model human biology, these results strengthen our confidence in RES-010’s profile as a first-in-class RNA therapy in obesity, with a clear differentiation from existing approaches.”
Phase 1 Trial Underway
RES-010 is currently undergoing evaluation in a Phase 1 clinical trial (EUCT No.: 2024-514871-17-00) involving healthy lean, overweight, and obese subjects. The trial, designed to assess safety, tolerability, and pharmacokinetic properties, is expected to yield preliminary data in mid-2026.
“these results underscore RES-010’s potential to reshape obesity treatment by offering benefits not achieved with existing approaches,” said a company representative. “Obesity is one of the fastest-growing health concerns worldwide, and there is a clear need for effective, durable, well-tolerated treatment options.We are excited to build on this momentum and are committed to our mission of transforming the standard of care in obesity.”
A New Era in Obesity Treatment?
Resalis Therapeutics believes RES-010 has the potential to complement and enhance the efficacy of existing anti-obesity drugs like GLP-1 receptor agonists, offering a more comprehensive therapeutic solution.By targeting miR-22, RES-010 aims to reduce fat mass across various body parts, including visceral fat and hepatic stores. The company is positioning itself as a key player in the evolving landscape of obesity treatment with its innovative RNA-based therapies.
For more information,visit www.resalistherapeutics.com.
